it must only be used within a registered clinical trial or approved early-access programme
When used in patients experiencing lower GI symptoms while taking GLP-1 medications, ARM allows clinicians to: Differentiate between drug-related motility effects and true pelvic floor dysfunction Quantify the severity of anorectal dysfunction to support diagnosis and treatment planning Establish a baseline prior to initiating biofeedback or behavioral therapy Monitor progress if conservative management is pursued Persistent Constipation in GLP-1 Users ARM can determine if dyssynergic defecation is contributing to delayed evacuation, guiding appropriate therapy beyond simply adjusting medication
The DELIVER trial randomized 6,263 patients with symptomatic HF, 74% of whom had NYHA class II symptoms, either with HF with moderately reduced ejection fraction (HFmrEF
From these three inputs, the calculator does one calculation twice: Concentration (mg/mL) = Vial content (mg) Diluent volume (mL) Injection volume (mL or units) = Target dose (mg) Concentration (mg/mL) A Worked Example Say a research vial contains 10mg of retatrutide, reconstituted with 2mL of bacteriostatic water
ClinicalTrials.gov: NCT04881760 (Phase 2, Obesity), NCT04867785 (Phase 2, T2D) Questions to ask your doctor Given my health history, is a GLP-1 medication appropriate for me at all
[1] By engaging the glucagon receptor alongside GLP-1 and GIP pathways, retatrutide is designed to drive greater caloric expenditure alongside appetite suppression
